Capricorn Partners

Capricorn Partners is a Leuven-based investor with deep roots in the Belgian deep tech and life sciences ecosystem, operating multiple thematic funds including its dedicated Healthtech Fund. The Healthtech Fund II vehicle gives the firm a structurally rigorous way to pursue digital health and personalized medicine, rather than treating healthcare as a sub-theme of a broader tech mandate.

The healthcare thesis covers digital health and medical devices and MedTech, with explicit positioning around personalized and value-based medicine. The disclosed portfolio anchor is icometrix, the Belgian neuroimaging AI company, which is a useful signal of the kind of clinically embedded software businesses the firm is built for. Capricorn is comfortable with regulatory complexity, clinical evidence requirements, and the longer development cycles that real medical technology demands, which differentiates it from generalist software investors operating with healthcare appetite.

The firm invests at Seed, Series A, and Series B, with checks of one to five million dollars and the ability to follow on through later rounds. The geographic focus is Europe with a Belgian center of gravity, and the firm operates as a credible lead or co-lead in clinically grounded health tech rounds. For founders building medical AI, devices, or clinically integrated software, the firm’s combination of regulatory pattern recognition and Benelux clinical relationships is a tangible asset, particularly for companies running their first clinical evidence work in Belgian or Dutch academic centers.

The team is built around partners with backgrounds in life sciences, healthcare investing, and deep tech, supported by the broader Capricorn platform. Specific partner names are not provided in the source material, and founders should clarify which partner leads the Healthtech Fund directly.

The right founders for Capricorn are clinically grounded health tech teams in medical AI, devices, and personalized medicine, where regulatory and clinical evidence are core to the business and the firm’s specialist lens improves the quality of the partnership. The wrong founders are pure software or workflow-tooling teams, where Capricorn’s thesis and pacing may feel mismatched. Founders should arrive with a credible clinical evidence plan, regulatory pathway, and a clear-eyed view of capital requirements through CE-mark, FDA, or reimbursement milestones. Capricorn rewards specificity in clinical and regulatory thinking and tends to be patient with companies whose value depends on getting those details right.